Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study
Identifieur interne : 000113 ( PascalFrancis/Corpus ); précédent : 000112; suivant : 000114Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study
Auteurs : U. Kuchler ; E. R. Luvizuto ; S. Tangl ; G. Watzek ; R. GruberSource :
- Journal of dental research [ 0022-0345 ] ; 2011.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Teriparatide is an anabolic osteoporosis therapeutic agent that can improve healing after fractures and periodontal surgeries. Clinical studies investigating the effects of teriparatide on the osseointegration of titanium implants have not been performed. We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws. The participants received 2 study implants in the mandible during interforaminal dental implant surgery. They were randomly assigned to receive either 20 μg of teriparatide once daily for 28 days or no treatment. Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses. Endpoints were new bone-volume-per-tissue-volume (NBV/TV) and new bone-to-implant-contact (NBIC). We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively. NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively. The results provide the first histological data on the osseointegration of titanium study implants in individuals treated with teriparatide. ClinicalTrials.gov number, NCT00089674. Abbreviations: NBV/ TV, new bone-volume per tissue volume; NBIC, new bone-to-implant contact; BV/TV, bone-volume per tissue volume; BIC, bone-to-implant contact; ROI, region of interest.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 11-0464099 INIST |
|---|---|
| ET : | Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study |
| AU : | KUCHLER (U.); LUVIZUTO (E. R.); TANGL (S.); WATZEK (G.); GRUBER (R.) |
| AF : | Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a/1090 Vienna/Autriche (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.); Austrian Cluster for Tissue Regeneration/Autriche (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Journal of dental research; ISSN 0022-0345; Etats-Unis; Da. 2011; Vol. 90; No. 8; Pp. 1001-1006; Bibl. 3/4 p. |
| LA : | Anglais |
| EA : | Teriparatide is an anabolic osteoporosis therapeutic agent that can improve healing after fractures and periodontal surgeries. Clinical studies investigating the effects of teriparatide on the osseointegration of titanium implants have not been performed. We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws. The participants received 2 study implants in the mandible during interforaminal dental implant surgery. They were randomly assigned to receive either 20 μg of teriparatide once daily for 28 days or no treatment. Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses. Endpoints were new bone-volume-per-tissue-volume (NBV/TV) and new bone-to-implant-contact (NBIC). We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively. NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively. The results provide the first histological data on the osseointegration of titanium study implants in individuals treated with teriparatide. ClinicalTrials.gov number, NCT00089674. Abbreviations: NBV/ TV, new bone-volume per tissue volume; NBIC, new bone-to-implant contact; BV/TV, bone-volume per tissue volume; BIC, bone-to-implant contact; ROI, region of interest. |
| CC : | 002B02L; 002B25C02; 002B02E |
| FD : | Tériparatide; Court terme; Activité biologique; Ostéointégration; Homme; Randomisation; Hormone parathyroïde; Dentisterie; Essai thérapeutique contrôlé; Antiostéoporotique; Traitement; Implant dentaire |
| FG : | Ostéoformateur |
| ED : | Teriparatide; Short term; Biological activity; Osteointegration; Human; Randomization; Parathyroid hormone; Dentistry; Controlled therapeutic trial; Antiosteoporotic; Treatment; Dental implant |
| EG : | Osteoforming |
| SD : | Teriparatida; Corto plazo; Actividad biológica; Osteointegración; Hombre; Aleatorización; Hormona paratiroidea; Odontología; Ensayo terapéutico controlado; Antiosteoporótico; Tratamiento |
| LO : | INIST-688.354000191183640080 |
| ID : | 11-0464099 |
Links to Exploration step
Pascal:11-0464099Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study</title><author><name sortKey="Kuchler, U" sort="Kuchler, U" uniqKey="Kuchler U" first="U." last="Kuchler">U. Kuchler</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Luvizuto, E R" sort="Luvizuto, E R" uniqKey="Luvizuto E" first="E. R." last="Luvizuto">E. R. Luvizuto</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tangl, S" sort="Tangl, S" uniqKey="Tangl S" first="S." last="Tangl">S. Tangl</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Watzek, G" sort="Watzek, G" uniqKey="Watzek G" first="G." last="Watzek">G. Watzek</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gruber, R" sort="Gruber, R" uniqKey="Gruber R" first="R." last="Gruber">R. Gruber</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">11-0464099</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 11-0464099 INIST</idno><idno type="RBID">Pascal:11-0464099</idno><idno type="wicri:Area/PascalFrancis/Corpus">000113</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study</title><author><name sortKey="Kuchler, U" sort="Kuchler, U" uniqKey="Kuchler U" first="U." last="Kuchler">U. Kuchler</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Luvizuto, E R" sort="Luvizuto, E R" uniqKey="Luvizuto E" first="E. R." last="Luvizuto">E. R. Luvizuto</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tangl, S" sort="Tangl, S" uniqKey="Tangl S" first="S." last="Tangl">S. Tangl</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Watzek, G" sort="Watzek, G" uniqKey="Watzek G" first="G." last="Watzek">G. Watzek</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gruber, R" sort="Gruber, R" uniqKey="Gruber R" first="R." last="Gruber">R. Gruber</name><affiliation><inist:fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation><affiliation><inist:fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Journal of dental research</title><title level="j" type="abbreviated">J. dent. res.</title><idno type="ISSN">0022-0345</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of dental research</title><title level="j" type="abbreviated">J. dent. res.</title><idno type="ISSN">0022-0345</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiosteoporotic</term><term>Biological activity</term><term>Controlled therapeutic trial</term><term>Dental implant</term><term>Dentistry</term><term>Human</term><term>Osteointegration</term><term>Parathyroid hormone</term><term>Randomization</term><term>Short term</term><term>Teriparatide</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Tériparatide</term><term>Court terme</term><term>Activité biologique</term><term>Ostéointégration</term><term>Homme</term><term>Randomisation</term><term>Hormone parathyroïde</term><term>Dentisterie</term><term>Essai thérapeutique contrôlé</term><term>Antiostéoporotique</term><term>Traitement</term><term>Implant dentaire</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Teriparatide is an anabolic osteoporosis therapeutic agent that can improve healing after fractures and periodontal surgeries. Clinical studies investigating the effects of teriparatide on the osseointegration of titanium implants have not been performed. We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws. The participants received 2 study implants in the mandible during interforaminal dental implant surgery. They were randomly assigned to receive either 20 μg of teriparatide once daily for 28 days or no treatment. Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses. Endpoints were new bone-volume-per-tissue-volume (NBV/TV) and new bone-to-implant-contact (NBIC). We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively. NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively. The results provide the first histological data on the osseointegration of titanium study implants in individuals treated with teriparatide. ClinicalTrials.gov number, NCT00089674. Abbreviations: NBV/ TV, new bone-volume per tissue volume; NBIC, new bone-to-implant contact; BV/TV, bone-volume per tissue volume; BIC, bone-to-implant contact; ROI, region of interest.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-0345</s0></fA01><fA03 i2="1"><s0>J. dent. res.</s0></fA03><fA05><s2>90</s2></fA05><fA06><s2>8</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study</s1></fA08><fA11 i1="01" i2="1"><s1>KUCHLER (U.)</s1></fA11><fA11 i1="02" i2="1"><s1>LUVIZUTO (E. R.)</s1></fA11><fA11 i1="03" i2="1"><s1>TANGL (S.)</s1></fA11><fA11 i1="04" i2="1"><s1>WATZEK (G.)</s1></fA11><fA11 i1="05" i2="1"><s1>GRUBER (R.)</s1></fA11><fA14 i1="01"><s1>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a</s1><s2>1090 Vienna</s2><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="02"><s1>Austrian Cluster for Tissue Regeneration</s1><s3>AUT</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA20><s1>1001-1006</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>688</s2><s5>354000191183640080</s5></fA43><fA44><s0>0000</s0><s1>© 2011 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>3/4 p.</s0></fA45><fA47 i1="01" i2="1"><s0>11-0464099</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of dental research</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Teriparatide is an anabolic osteoporosis therapeutic agent that can improve healing after fractures and periodontal surgeries. Clinical studies investigating the effects of teriparatide on the osseointegration of titanium implants have not been performed. We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws. The participants received 2 study implants in the mandible during interforaminal dental implant surgery. They were randomly assigned to receive either 20 μg of teriparatide once daily for 28 days or no treatment. Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses. Endpoints were new bone-volume-per-tissue-volume (NBV/TV) and new bone-to-implant-contact (NBIC). We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively. NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively. The results provide the first histological data on the osseointegration of titanium study implants in individuals treated with teriparatide. ClinicalTrials.gov number, NCT00089674. Abbreviations: NBV/ TV, new bone-volume per tissue volume; NBIC, new bone-to-implant contact; BV/TV, bone-volume per tissue volume; BIC, bone-to-implant contact; ROI, region of interest.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02L</s0></fC02><fC02 i1="02" i2="X"><s0>002B25C02</s0></fC02><fC02 i1="03" i2="X"><s0>002B02E</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Tériparatide</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Teriparatide</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Teriparatida</s0><s2>NK</s2><s2>FR</s2><s5>04</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Court terme</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Short term</s0><s5>07</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Corto plazo</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Activité biologique</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Biological activity</s0><s5>08</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Actividad biológica</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Ostéointégration</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Osteointegration</s0><s5>09</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Osteointegración</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0><s5>13</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Human</s0><s5>13</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Randomisation</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Randomization</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Aleatorización</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Hormone parathyroïde</s0><s2>FR</s2><s5>15</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Parathyroid hormone</s0><s2>FR</s2><s5>15</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Hormona paratiroidea</s0><s2>FR</s2><s5>15</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Dentisterie</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Dentistry</s0><s5>16</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Odontología</s0><s5>16</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Essai thérapeutique contrôlé</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Controlled therapeutic trial</s0><s5>17</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Ensayo terapéutico controlado</s0><s5>17</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Antiostéoporotique</s0><s5>30</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Antiosteoporotic</s0><s5>30</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Antiosteoporótico</s0><s5>30</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Traitement</s0><s5>31</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Treatment</s0><s5>31</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento</s0><s5>31</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Implant dentaire</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Dental implant</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Ostéoformateur</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Osteoforming</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Osteoformador</s0><s5>37</s5></fC07><fN21><s1>319</s1></fN21></pA></standard><server><NO>PASCAL 11-0464099 INIST</NO><ET>Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study</ET><AU>KUCHLER (U.); LUVIZUTO (E. R.); TANGL (S.); WATZEK (G.); GRUBER (R.)</AU><AF>Department of Oral Surgery, Medical University of Vienna, Sensengasse 2a/1090 Vienna/Autriche (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.); Austrian Cluster for Tissue Regeneration/Autriche (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Journal of dental research; ISSN 0022-0345; Etats-Unis; Da. 2011; Vol. 90; No. 8; Pp. 1001-1006; Bibl. 3/4 p.</SO><LA>Anglais</LA><EA>Teriparatide is an anabolic osteoporosis therapeutic agent that can improve healing after fractures and periodontal surgeries. Clinical studies investigating the effects of teriparatide on the osseointegration of titanium implants have not been performed. We conducted an open-label randomized controlled feasibility study and included 24 individuals with edentulous lower jaws. The participants received 2 study implants in the mandible during interforaminal dental implant surgery. They were randomly assigned to receive either 20 μg of teriparatide once daily for 28 days or no treatment. Study implants were retrieved from 23 participants after 9 weeks and were subjected to histomorphometric analyses. Endpoints were new bone-volume-per-tissue-volume (NBV/TV) and new bone-to-implant-contact (NBIC). We report here that median values of NBV/TV in the control and the teriparatide groups were 15.4% vs. 17.6% in the periosteal compartment, 11.3% vs. 16.5% in the cortical compartment, and 7.3% vs. 12.0% in the medullary compartment, respectively. NBIC median values in the control and the teriparatide groups were 3.3% vs. 4.1% in the periosteal compartment, 5.0% vs. 4.4% in the cortical compartment, and 0.3% vs. 1.4% in the medullary compartment, respectively. The results provide the first histological data on the osseointegration of titanium study implants in individuals treated with teriparatide. ClinicalTrials.gov number, NCT00089674. Abbreviations: NBV/ TV, new bone-volume per tissue volume; NBIC, new bone-to-implant contact; BV/TV, bone-volume per tissue volume; BIC, bone-to-implant contact; ROI, region of interest.</EA><CC>002B02L; 002B25C02; 002B02E</CC><FD>Tériparatide; Court terme; Activité biologique; Ostéointégration; Homme; Randomisation; Hormone parathyroïde; Dentisterie; Essai thérapeutique contrôlé; Antiostéoporotique; Traitement; Implant dentaire</FD><FG>Ostéoformateur</FG><ED>Teriparatide; Short term; Biological activity; Osteointegration; Human; Randomization; Parathyroid hormone; Dentistry; Controlled therapeutic trial; Antiosteoporotic; Treatment; Dental implant</ED><EG>Osteoforming</EG><SD>Teriparatida; Corto plazo; Actividad biológica; Osteointegración; Hombre; Aleatorización; Hormona paratiroidea; Odontología; Ensayo terapéutico controlado; Antiosteoporótico; Tratamiento</SD><LO>INIST-688.354000191183640080</LO><ID>11-0464099</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000113 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000113 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= EdenteV2
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:11-0464099
|texte= Short-term Teriparatide Delivery and Osseointegration: a Clinical Feasibility Study
}}
| This area was generated with Dilib version V0.6.32. |  |